Investor relations

NeuroVive Pharmaceutical AB is listed on AktieTorget. The AktieTorget market is focused on emerging, entrepreneurial businesses and offers an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

NeuroVive Pharmaceutical AB raised  $1.5 million through the IPO financing round. Funds will be used to ramp up production to full manufacturing in three runs to support a New Drug Application with regulatory authorities in the US, Europe and Japan. There will be rapid manufacture of clinical trial supplies of the NeuroSTAT® formulation and a clinical safety trial for NeuroSTAT®.  NeuroSTAT® will be suitable for participation in traumatic brain injury clinical studies in the United States.

A full prospectus (in Swedish) is available on the Swedish company website and the AktieTorget stock exchange homepage

The trading of NeuroVive Pharmaceutical AB shares can be monitored at the AktieTorget stock exchange homepage

A brief NVP company profile is found at Google Finance